SCHEMBL537893

SCHEMBL537893

CCCCNc1nc2c3c(n[nH]c3n1)CCN2Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.40
CASP6 P55212 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BRS3 P32247 1/20 0.38
TLR7 Q9NYK1 6/20 0.38
TLR8 Q9NR97 1/20 0.38
SLC2A1 P11166 1/20 0.37
FLT3 P36888 2/20 0.37
TYRO3 Q06418 2/20 0.37
MERTK Q12866 2/20 0.37
GAS6 Q14393 2/20 0.37
KCNH3 Q9ULD8 1/20 0.37
POLB P06746 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2811997 0.90 KDM1A (0.44)
SCHEMBL2811941 0.89 CLPP (0.41) ALDH1A1LMNAHTTSMN1; SMN2BRS3
SCHEMBL537947 0.87 HRH3 (0.42) ALDH1A1SMN1; SMN2BRS3KDM4E
SCHEMBL2816633 0.87 LMNA (0.43) ALDH1A1LMNABRS3KDM4E
SCHEMBL14405859 0.86 HRH4 (0.41) LMNAHTTPOLB
SCHEMBL2814500 0.86 LMNA (0.48) ALDH1A1TSHRLMNATP53MAPK1
SCHEMBL2810352 0.85 BRS3 (0.40) ALDH1A1MAPK1SMN1; SMN2BRS3KDM4E
SCHEMBL2814442 0.85 CLPP (0.39) ALDH1A1LMNABRS3SLC2A1KDM4E
SCHEMBL2808422 0.85 MRGPRX1 (0.40)
SCHEMBL14405855 0.85 SIGMAR1 (0.43) ALDH1A1LMNASMN1; SMN2BRS3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP claimed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO claimed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 ALDH1A1 924/4885TSHR 3555/4885CASP6 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.